New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 6, 2014
10:14 EDTJNJFDA approves label change for Doribax describing increased risk of death
The FDA announced it has concluded that Doribax, an antibacterial drug that has been used to treat patients who develop pneumonia while on ventilators, carries an increased risk of death and lower clinical cure rates compared to use of imipenem and cilastatin for injection, marketed in the U.S. under the name Primaxin. "Based on our analysis of data from a three-year clinical trial that was prematurely stopped in 2011 due to these safety concerns, we have approved changes to the Doribax drug label that describe these risks," the FDA stated. The FDA said Doribax is still considered safe and effective for its FDA-approved indications - treatment of adults with complicated intra-abdominal infections and complicated urinary tract infections. Doribax is marketed outside Japan by Johnson & Johnson.
News For JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 3, 2015
18:11 EDTJNJSiemens investigated by Chinese regulator last year, Reuters says
Subscribe for More Information
May 1, 2015
16:49 EDTJNJJ&J says Costco filed complaint against Vision Care unit
Subscribe for More Information
07:43 EDTJNJExpensive drugs drove over 25% of 2013 Medicare drug spending, WSJ says
Subscribe for More Information
April 29, 2015
17:00 EDTJNJJohnson & Johnson announces further patent action related to Remicade
Subscribe for More Information
12:25 EDTJNJPerrigo rumored to possibly draw interest beyond Mylan bid, Bloomberg says
Subscribe for More Information
April 27, 2015
06:19 EDTJNJPharmceutical companies buy drugs and raises prices, WSJ reports
Subscribe for More Information
April 23, 2015
14:20 EDTJNJEarnings Watch: Google up close to 8.5% since last earnings report
Subscribe for More Information
11:02 EDTJNJJohnson & Johnson increases dividend by 7.1% to 75c
Subscribe for More Information
10:02 EDTJNJAbbVie says communication with Johnson & Johnson has been 'very positive'
Subscribe for More Information
April 20, 2015
14:32 EDTJNJPharmacyclics patent for Imbruvica challenged by Hayman Capital's Bass
Subscribe for More Information
06:59 EDTJNJJohnson & Johnson added to short-term buy list at Deutsche Bank
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use